Skip to content
PubMed This is a summary of 67 peer-reviewed journal articles Updated
Gastroenterology

Zollinger-Ellison Syndrome: A Patient Guide

At a Glance

Zollinger-Ellison syndrome is caused by gastrin-producing tumors that drive excess stomach acid, leading to recurrent ulcers and watery diarrhea. High-dose proton pump inhibitors control the acid, while surgery or long-term monitoring depends on tumor features and whether MEN1 is involved.

Zollinger-Ellison Syndrome (ZES) is a rare condition characterized by the development of one or more tumors called gastrinomas [1]. These tumors, typically found in the pancreas or the upper part of the small intestine, release an excessive amount of a hormone called gastrin. In a healthy body, gastrin acts as a messenger that tells the stomach to produce acid for digestion; however, in ZES, the tumors constantly signal the digestive system to produce excess gastric acid regardless of whether you have eaten [2]. This persistent overproduction overwhelms the body’s natural defenses, leading to severe, recurrent peptic ulcers and chronic, watery diarrhea [3].

Living with ZES requires managing two distinct but related medical challenges: the immediate danger of the stomach acid and the long-term management of the tumor itself. The excessive acid is not just a source of discomfort; if left untreated, it can cause severe complications like internal bleeding or a perforation (hole) in the stomach or intestinal lining [4]. To prevent this, the cornerstone of care is the use of high-dose acid-blocking medications known as proton pump inhibitors (PPIs). Because the gastrinomas are constantly signaling for acid, these medications must be taken consistently and should never be stopped abruptly or changed without medical supervision, as doing so can trigger a dangerous return of severe symptoms [5].

The underlying tumors can occur in two different ways. For many, a gastrinoma is a single, “sporadic” event that happens by chance. For others, it is part of a hereditary condition called Multiple Endocrine Neoplasia type 1 (MEN1), which may involve tumors in other hormone-producing glands like the parathyroid or pituitary [5][6]. Identifying which type of ZES you have is vital. While sporadic disease is sometimes approached with curative surgery (though not always, depending on whether it has spread), MEN1-associated ZES often requires a complex, long-term monitoring strategy to manage multiple small tumors over many years [7][8]. Your treatment decisions will depend on tumor location, grade, stage, and your personal health.

While a ZES diagnosis can feel overwhelming, modern medicine provides highly effective tools to control both the acid and the tumor. With the right team of specialists—including experts in gastroenterology, surgery, endocrinology, and oncology—most patients are able to find a balance that heals their ulcers, stops their symptoms, and allows them to focus on their long-term health and well-being [2][9]. Living with ZES is a journey of careful management, but it is one that can be navigated successfully with consistent care and a well-coordinated treatment plan [4].

Common questions in this guide

What is Zollinger-Ellison syndrome, and what causes it?
Zollinger-Ellison syndrome is a rare condition caused by one or more gastrinomas, which are tumors that release the hormone gastrin. Excess gastrin signals the stomach to produce too much acid, even when you have not eaten.
What symptoms can Zollinger-Ellison syndrome cause?
Symptoms may include severe, recurring peptic ulcers, chronic watery diarrhea, and ongoing pain. Excess acid can also damage the stomach or intestinal lining and cause serious bleeding or a perforation.
Why are proton pump inhibitors important for ZES?
Proton pump inhibitors, or PPIs, reduce the stomach acid driven by excess gastrin. In ZES they are the main treatment for protecting the digestive lining and helping ulcers heal, so they generally need to be taken consistently. Do not stop or change them without medical guidance because severe symptoms can return.
Is Zollinger-Ellison syndrome connected to MEN1?
Yes. In some people, ZES is part of inherited Multiple Endocrine Neoplasia type 1, or MEN1, which can also affect the parathyroid and pituitary glands. Your healthcare team may recommend evaluating for MEN1 because it changes how tumors are monitored and treated.
Can surgery cure Zollinger-Ellison syndrome?
Surgery may offer a potential cure for some people with sporadic ZES, depending on where the gastrinoma is located and whether it has spread. In MEN1-associated ZES, several small tumors may require long-term monitoring and individualized treatment rather than one curative operation. Tumor grade, stage, location, and overall health all influence the plan.
What should I do if I cannot take my acid-blocking medicine?
Contact your healthcare team promptly for an emergency or backup plan rather than stopping the medicine on your own. Abruptly missing or changing acid-blocking treatment can allow severe acid-related symptoms to return and may increase the risk of complications.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How much experience does our medical center have in managing neuroendocrine tumors and gastrinomas specifically?
  2. 2.Is my ZES likely sporadic, or do I need to be screened for the MEN1 genetic syndrome?
  3. 3.What is the long-term plan for monitoring both my stomach acid levels and the behavior of the tumor?
  4. 4.If I am unable to take my acid-blocking medication for any reason, what is my emergency backup plan?
  5. 5.Can you explain the specific goals of my treatment—is it aimed at symptom management, tumor control, or a potential cure?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (9)
  1. 1

    All you need to know about gastrinoma today | Gastrinoma and Zollinger-Ellison syndrome: A thorough update.

    Chatzipanagiotou O, Schizas D, Vailas M, et al.

    Journal of neuroendocrinology 2023; (35(4)):e13267 doi:10.1111/jne.13267.

    PMID: 37042078
  2. 2

    Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies.

    Rossi RE, Elvevi A, Citterio D, et al.

    World journal of gastroenterology 2021; (27(35)):5890-5907 doi:10.3748/wjg.v27.i35.5890.

    PMID: 34629807
  3. 3

    Hypergastrinemia.

    Dacha S, Razvi M, Massaad J, et al.

    Gastroenterology report 2015; (3(3)):201-8 doi:10.1093/gastro/gov004.

    PMID: 25698559
  4. 4

    Total gastrectomy for severe proton pump inhibitor-induced hypomagnesemia in a MEN1/Zollinger Ellison syndrome patient.

    Perrier M, Delemer B, Deguelte S, et al.

    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2021; (21(1)):236-239 doi:10.1016/j.pan.2020.12.002.

    PMID: 33309626
  5. 5

    Assessing for Multiple Endocrine Neoplasia Type 1 in Patients Evaluated for Zollinger-Ellison Syndrome-Clues to a Safer Diagnostic Process.

    Singh Ospina N, Donegan D, Rodriguez-Gutierrez R, et al.

    The American journal of medicine 2017; (130(5)):603-605 doi:10.1016/j.amjmed.2016.11.035.

    PMID: 28011308
  6. 6

    [Comparison of clinical characteristics between sporadic gastrinoma and multiple endocrine neoplasia type 1-related gastrinoma].

    Guo Y, Chen LH, Liu M, et al.

    Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery 2021; (24(10)):875-882 doi:10.3760/cma.j.cn.441530-20210719-00291.

    PMID: 34674462
  7. 7

    How to treat gastrinomas in patients with multiple endocrine neoplasia type1: surgery or long-term proton pump inhibitors?

    Imamura M, Komoto I, Taki Y

    Surgery today 2023; (53(12)):1325-1334 doi:10.1007/s00595-022-02627-z.

    PMID: 36473964
  8. 8

    Surgical management of Zollinger-Ellison syndrome: Classical considerations and current controversies.

    Shao QQ, Zhao BB, Dong LB, et al.

    World journal of gastroenterology 2019; (25(32)):4673-4681 doi:10.3748/wjg.v25.i32.4673.

    PMID: 31528093
  9. 9

    [Management of gastrinoma].

    Hain E, Coriat R, Dousset B, Gaujoux S

    Presse medicale (Paris, France : 1983) 2016; (45(11)):986-991 doi:10.1016/j.lpm.2016.04.012.

    PMID: 27262229

This page explains Zollinger-Ellison syndrome, gastrinomas, and long-term treatment for informational purposes only; it does not constitute medical advice. Do not stop or change acid-blocking medicine without guidance from your healthcare team.

Get notified when new evidence is published on Zollinger-Ellison syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.